RecruitingPhase 2NCT06906874

Activated Charcoal Use in Chronic Kidney Disease Patients

Efficacy and Safety of Activated Charcoal on Mineral Bone Disorder in Chronic Kidney Disease Patients

Sponsor

Mansoura University

Enrollment

40 participants

Start Date

Aug 1, 2025

Study Type

INTERVENTIONAL

Conditions

End Stage Renal Disease (ESRD)CKD 5D, Hemodialysis CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder

Summary

Hyperphosphatemia management is initially based on restricting dietary phosphorus intake. Hyperphosphatemia is almost always seen in patients on dialysis and may contribute to progressive vascular calcification. Considering that activated charcoal is generally well-tolerated and may have a favorable side effect profile compared to conventional phosphate binders, it presents a promising alternative. Until now, no clinical trial has primarily investigated the effect of activated charcoal on hyperphosphatemia in dialysis patients.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether activated charcoal can help kidney disease patients who are on dialysis manage phosphate levels in their blood more effectively. **You may be eligible if...** - You are 18 or older with end-stage kidney disease (ESRD) - You have been on regular hemodialysis (3 times a week) for at least 6 months - You are already taking phosphate binders as part of your standard care **You may NOT be eligible if...** - You are severely malnourished - You are on overnight dialysis - You have a parathyroid gland problem or very high parathyroid hormone levels (over 800 pg/mL) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.